Targeting the last enzyme DHCR7 would also make this inhibition even more selective. Together, the tumor-specific dependency of RMS and the compensatory capacity of normal cells strongly position cholesterol metabolism as an exploitable therapeutic vulnerability. Here, DHCR7 is linked to neoplasm.